 NEW YORK, May 25, 2022 GLOBE NEWSWIRE -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T iNKT cell therapies to treat cancer and other immune-mediated diseases, announced that its virtual-only Annual Meeting of Shareholders will be held at 5:00 PM ET on June 8, 2022. 